Prognostic value of bone marrow angiogenesis in multiple myeloma

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3111-3116

  Rajkumar, S Vincent ^a   Leong, Traci ^b   Roche, Patrick C ^a   Fonseca, Rafael ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Lust, John A ^a   Witzig, Thomas E ^a   Kyle, Robert A ^a   Gertz, Morie A ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

^b Eastern Cooperative Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHO FACTOR; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER SURVIVAL; CELL LABELING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS;

BONE MARROW; CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PLASMA CELLS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 0033902037     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Bataille, R., and Harousseau, J. L. Multiple myeloma. N. Engl. J. Med., 336: 1657-1664, 1997.
3. Kyle, R. A. Long-term survival in multiple myeloma. N. Engl. J. Med., 308: 314-316, 1983.
4. Harousseau, J. L., and Altal, M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin. Hematol., 34: 61-66, 1997.
5. Barlogie, B., Hall, R., Zander, A., Dicke, K., and Alexanian, R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood, 67: 1298-301, 1986.
6. Altal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G., Rossi, J. F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., and Bataille, R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med., 335: 91-97, 1996.
7. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
8. Folkman, J. Seminars in Medicine of the Beth Israel Hospital. Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
9. Folkman, J. New perspectives in clinical oncology from angiogenesis research. Eur. J. Cancer, 14: 2534-2539, 1996.
10. Bostwick, D. G., Wheeler, T. M., Blute, M., Barrett, D. M., MacLennan, G. T., Sebo, T. J., Scardino, P. T., Humphrey, P. A., Hudson, M. A., Fradet, Y., Miller, G. J., Crawford, E. D., Blumenstein, B. A., Mahran, H. E., and Miles, B. J. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology, 48: 47-57, 1996.
11. Dickinson, A. J., Fox, S. B., Persad, R. A., Hollyer, J., Sibley, G. M., and Harris, A. L. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br. J. Urol., 74: 762-766, 1994.
12. Fox, S. B., Leek, R. D., Weekes, M. P., Whitehouse, R. M., Gatter, K. C., and Harris, A. L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density. Chalkley count and computer image analysis. J. Pathol., 177: 275-283, 1995.
13. Fox, S. B. Tumour angiogenesis and prognosis. Histopathology, 30: 294-301, 1997.
14. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
15. Rajkumar, S. V., Fonseca, R., Witzig, T. E., Gertz, M. A., and Greipp, P. R. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia (Baltimore), 13: 469-472, 1999.
16. Perez-Atayde, A. R., Sallan, S. E., Tedrow, U., Connors, S., Allred, E., and Folkman, J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol., 150: 815-821, 1997.
17. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., and Dammacco, F. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol., 87: 503-508, 1994.
18. Vacca, A., Ribatti, D., Roncali, L., and Dammacco, F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk. Lymphoma, 20: 27-38, 1995.
19. Vacca, A., Di Loreto, M., Ribatti, D., Di Stefano, R., Gadaleta-Caldarola, G., Iodice, G., Caloro, D., and Dammacco, F. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am. J Hematol., 50: 9-14, 1995.
20. Greipp, P. R., Lust, J. A., O'Fallon, W. M., Katzmann, J. A., Witzig, T. E., and Kyle, R. A. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood, 81: 3382-3387, 1993.
21. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L., McCulloch, P., Pezzella, F., Viale, G., Weidner, N., Harris, A. L., and Dirix, L. Y. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer, 14: 2474-2484, 1996.
22. Rajkumar, S. V., Fonseca, R., Ansell, S. M., Witzig, T. E., Gertz, M. A., and Greipp, P. R. Computerized image analysis in the assessment of bone marrow angiogenesis in multiple myeloma. Blood, 92 (Suppl. 1): 100a, 1998.
23. Fox, S. B., Gatter, K. C., and Harris, A. L. Tumour angiogenesis. J. Pathol., 779: 232-237, 1996.
24. Witzig, T. E., Gonchoroff, N. J., Katzmann, J. A., Therneau, T. M., Kyle, R. A., and Greipp, P. R. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J. Clin Oncol., 6: 1041-1046, 1988.
25. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
26. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. (B), 34: 187-202, 1972.
27. Rajkumar, S. V., Fonseca, R., Witzig, T. E., Gertz, M. A., and Greipp, P. R. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Blood, 92(Suppl. 1): 99a, 1998.
28. Munshi, N., Wilson, C. S., Penn, J., Epstein, J., Singhal, S., Hough, A., Sanderson, R., Desikan, R., Siegel, D., Mehta, J., and Barlogie, B. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies Blood, 92: 98a, 1998.
29. Rajkumar, S. V., Fonseca, R., Lacy, M. Q., Witzig, T. E., Therneau, T. M., Kyle, R. A., Litzow, M. R., Gertz, M. A., and Greipp, P. R. Plasmablastic morphology is an independent predictor of poor survival after autologous stem cell transplantation for multiple myeloma. J. Clin. Oncol., 17: 1551-1557, 1999.
30. Rajkumar, S. V., Fonseca, R., Lacy, M. Q., Witzig, T. E., Lust, J. A., Greipp, P. R., Therneau, T. M., Kyle, R. A., Litzow, M. R., and Gertz, M. A. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplantation, 24: 497-503, 1999.
31. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
32. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88: 277-285, 1997.
33. Twardowski, P., and Gradishar, W. J. Clinical trials of antiangiogenic agents. Curr. Opin. Oncol., 9: 584-589, 1997.
34. Singhal, S., Mehta, S., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J., and Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 341: 1565-1571, 1999.
35. Rajkumar, S. V., Fonseca, R., Dispenzieri, A., Lacy, M. Q., Witzig, T. E., Kyle, R. A., Gertz, M. A., and Greipp, P. R. Thalidomide in the treatment of relapsed and refractory myeloma. Blood, 94 (Suppl. 1): 316a, 1999.
36. Ito, A., Hirota, S., Mizuno, H., Kawasaki, Y., Takemura, T., Nishiura, T., Kanakura, Y., Katayama, Y., Nomura, S., and Kitamura, Y. Expression of vascular permeability factor (VPF/VEGF) messenger RNA by plasma cells: possible involvement in the development of edema in chronic inflammation. Pathol. Int., 45: 715-720, 1995.
37. Bellamy, W. T., Richter, L., Frutiger, Y., and Grogan, T. M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res., 59: 728-733, 1999.
38. Rajkumar, S. V., Yoon, S. Y., Li, C. Y., Roche, P. C., Fonseca, R., Dispenzieri, A., Lacy, M. Q., Lust, J. A., Gertz, M. A., Kyle, R. A., Greipp, P. R., and Witzig, T. E. Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells. Blood, 94: 303b, 1999.
39. Dankbar, B., Padro, T., Mesters, R. M., Leo, R., Ostermann, H., Serve, H., Berdel, W. E., and Kienast, J. VEGF is expressed by myeloma cells and stimulates IL-6 secretion by microvascular endothelial and marrow stromal cells. Blood, 92 (Suppl. 1): 681a, 1998.